Full text is available at the source.
Abstract
A framework for correcting Wiskott-Aldrich syndrome using a CRISPR-Cas9-AAV6 platform shows a largely favorable safety profile.
- The platform enables large-scale manufacturing of hematopoietic stem and progenitor cells while maintaining their viability and functionality.
- Fine-tuning AAV dosing and modulating the DNA damage response pathway led to improved correction and repopulation in living organisms.
- A multi-tiered genotoxicity assessment revealed minimal off-target risks and no evidence of clonal dominance or transformation during the study.
- Longitudinal monitoring showed rare off-target events and structural variants specific to the donor, underscoring the need for ongoing patient monitoring.
- A specific chromosomal rearrangement was identified only after cell engraftment in mice, highlighting potential post-transplantation risks.
Simplified